Action 603087 GAN & LEE PHARMACEUTICALS.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Gan & Lee Pharmaceuticals.

Actions

603087

CNE100003ZH1

Cours en clôture Shanghai S.E.
Autres places de cotation
 00:00:00 28/06/2024 		Varia. 5j. Varia. 1 janv.
46,32 CNY -1,19 % Graphique intraday de Gan & Lee Pharmaceuticals. -2,67 % -12,02 %
24/04 Gan & Lee Pharmaceuticals. annonce ses résultats pour le premier trimestre clos le 31 mars 2024 CI
24/04 Gan & Lee Pharmaceuticals. annonce ses résultats pour l'exercice clos le 31 décembre 2023 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Gan & Lee Pharmaceuticals Announces Significant Progress on New Diabetes and Obesity Treatments at the American Diabetes Association's 84th Scientific Sessions
Gan & Lee Pharmaceuticals to Present Groundbreaking Data on Three Innovative Products at the American Diabetes Association's 84th Scientific Sessions
Gan & Lee Pharmaceuticals.(SHSE:603087) added to SSE 180 Index
Gan & Lee Pharmaceuticals.(SHSE:603087) added to Shanghai Stock Exchange 180 Value Index
Gan & Lee Pharmaceuticals Gets Mexico's Drug Registration Approval for Insulin Glargine Injection
Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 31, 2024
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Full Year Ended December 31, 2023
Gan & Lee Pharma's Insulin Product Gets Registration Approval in Bolivia
Gan & Lee Pharmaceuticals Administers First Subject in Phase II Study of GZR101 Diabetes Drug
Gan & Lee Pharmaceuticals' Unit Gets Nod to Test GZR18 Tablets
Gan & Lee Pharmaceuticals. announced that it has received CNY 773.151876 million in funding
Type 1 Diabetes Pipeline| Clinical Trials and Key Companies - Landos Biopharma, Diamyd Medical, Gan&Lee Pharmaceuticals, Zealand Pharma
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Nine Months Ended September 30, 2023
Gan & Lee Pharma’s Insulin Analogs Gain EU Regulatory Approval
Gan & Lee Pharmaceuticals.(XSSC:603087) added to S&P Global BMI Index
Gan & Lee Pharmaceuticals.(XSSC:603087) added to FTSE All-World Index
Gan & Lee Pharma Advances Trial of New Insulin Product
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Half Year Ended June 30, 2023
Gan & Lee Pharmaceuticals Gets Nod to Trial GLR1023 Injection
Gan & Lee Pharmaceuticals Gets Regulatory Nod for Private Placement
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 603087
  4. Actualités Gan & Lee Pharmaceuticals.
  5. Autres langues